Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07163936 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Analysis of the Influence of Dialysis Fluid Composition on Vascular Calcification in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Study acronym: CalCio-HD
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 3 months later Sep 6, 2026 → Jan 2, 2028
See other at-risk trials from Hospital Clinic of Barcelona

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 6, 2026 to Jan 2, 2028
    • Start date: Sep 3, 2025 to Jan 2, 2027
    • Eligibility criteria expanded, about 10 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to find out if using a citrate-based dialysate with added magnesium during hemodialysis can help slow down or prevent the hardening of blood vessels (vascular calcification) in adults on long-term dialysis. The main questions the study will try to answer are: Does citrate-based dialysate with magnesium improve the blood's ability to prevent calcium buildup (measured by a test called T50) compared to acetate-based dialysate? Does it modify magnesium, calcium and parathyroid hormone (PTH) levels in the blood? Does it lower the chances of heart problems or death? Researchers will compare two groups: one will receive acetate-based dialysate, and the other will receive citrate-based dialysate with magnesium. Participants will: Receive one of the two types of dialysate during their regular hemodialysis sessions for 12 months Have regular blood tests Be monitored for any heart problems and for overall health during the study
Trial Details
NCT Number NCT07163936
Lead Sponsor Hospital Clinic of Barcelona
Conditions
(from sponsor)		 Vascular Calcification, Hemodialysis, Cardiovascular Disease (CKD)
Related terms Cardiovascular Diseases, Vascular Calcification
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov